The global lung cancer diagnostics market size was estimated at USD 12.37 billion in 2024 and is projected to reach USD 23.31 billion by 2033, growing at a CAGR of 7.5% from 2025 to 2033. The market encompasses diagnostic technologies designed to facilitate the early detection and accurate classification of lung cancer, which remains one of the leading causes of cancer-related mortality worldwide.
A broad range of diagnostic modalities, such as imaging techniques, molecular tests, and biopsy-based assessments, are employed to support clinical decision-making. The adoption of advanced molecular diagnostics and liquid biopsy methods is gaining traction, driven by the rising focus on personalized medicine and the identification of actionable genetic mutations for targeted therapy.
Growing awareness about the importance of early cancer detection, coupled with ongoing developments in imaging systems and next-generation sequencing platforms, is shaping the market landscape. The integration of AI-based image analysis and the expansion of point-of-care testing solutions are also improving diagnostic accuracy and reducing turnaround times. In addition, increased screening programs, particularly in high-risk populations, and supportive initiatives by health authorities are accelerating the demand for innovative diagnostic tools. These factors contribute to the growth of the global lung cancer diagnostics industry.
Worldwide, lung cancer is the second leading and most occurring cancer in men. However, in several countries, lung cancer has become one of the prominent causes of cancer-related deaths. The common symptoms include hemoptysis, cough, or systemic symptoms such as weight loss or anorexia that increase the chances of developing chronic conditions, including cancer. The WHO estimates around 1.80 million deaths due to lung cancer worldwide annually. Excessive smoking habits are highly prevalent in men, and tobacco exposure contains around 7,000 chemicals, with more than 50 known cancer-causing chemicals. Therefore, excessive tobacco consumption and smoking are likely to be significant factors for lung screening and diagnostics.
Over the past few years, there has been a prominent rise in patients with chronic lung cancers irrespective of smoking. For instance, patients with small-cell lung cancer (SCLC) may or may not have a smoking history. However, 15 to 20 percent of patients are exposed to secondhand or passive smoking. Besides smoking, other factors such as radon exposure, asbestos, genetics, air pollution, and dietary factors develop chronic conditions in patients. Genetics and asbestos account for a high probability of developing cancerous conditions in patients.
Overall, the global lung cancer diagnostics industry is progressing toward more precise, faster, and less invasive diagnostic approaches. Continuous integration of AI, NGS, and liquid biopsy solutions is streamlining clinical workflows and enabling early detection, which is essential for improving patient outcomes. Growing investments in innovative technologies and the expansion of screening initiatives are expected to further strengthen diagnostic capabilities across healthcare systems.
This product will be delivered within 1-3 business days.
A broad range of diagnostic modalities, such as imaging techniques, molecular tests, and biopsy-based assessments, are employed to support clinical decision-making. The adoption of advanced molecular diagnostics and liquid biopsy methods is gaining traction, driven by the rising focus on personalized medicine and the identification of actionable genetic mutations for targeted therapy.
Growing awareness about the importance of early cancer detection, coupled with ongoing developments in imaging systems and next-generation sequencing platforms, is shaping the market landscape. The integration of AI-based image analysis and the expansion of point-of-care testing solutions are also improving diagnostic accuracy and reducing turnaround times. In addition, increased screening programs, particularly in high-risk populations, and supportive initiatives by health authorities are accelerating the demand for innovative diagnostic tools. These factors contribute to the growth of the global lung cancer diagnostics industry.
Worldwide, lung cancer is the second leading and most occurring cancer in men. However, in several countries, lung cancer has become one of the prominent causes of cancer-related deaths. The common symptoms include hemoptysis, cough, or systemic symptoms such as weight loss or anorexia that increase the chances of developing chronic conditions, including cancer. The WHO estimates around 1.80 million deaths due to lung cancer worldwide annually. Excessive smoking habits are highly prevalent in men, and tobacco exposure contains around 7,000 chemicals, with more than 50 known cancer-causing chemicals. Therefore, excessive tobacco consumption and smoking are likely to be significant factors for lung screening and diagnostics.
Over the past few years, there has been a prominent rise in patients with chronic lung cancers irrespective of smoking. For instance, patients with small-cell lung cancer (SCLC) may or may not have a smoking history. However, 15 to 20 percent of patients are exposed to secondhand or passive smoking. Besides smoking, other factors such as radon exposure, asbestos, genetics, air pollution, and dietary factors develop chronic conditions in patients. Genetics and asbestos account for a high probability of developing cancerous conditions in patients.
Overall, the global lung cancer diagnostics industry is progressing toward more precise, faster, and less invasive diagnostic approaches. Continuous integration of AI, NGS, and liquid biopsy solutions is streamlining clinical workflows and enabling early detection, which is essential for improving patient outcomes. Growing investments in innovative technologies and the expansion of screening initiatives are expected to further strengthen diagnostic capabilities across healthcare systems.
Global Lung Cancer Diagnostics Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. The analyst has segmented the lung cancer diagnostics market report based on type, test, end use, and region:Type Outlook (Revenue, USD Million, 2021-2033)
- Non-small cell lung cancer
- Small cell lung cancer
Test Outlook (Revenue, USD Million, 2021-2033)
- CA test
- HER2 test
- ALK test
- Angiogenesis Inhibitors
- EGFR Mutation test
- KRAS Mutation test
End Use Outlook (Revenue, USD Million, 2021-2033)
- Hospitals
- Laboratories
- Others
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the industry across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segmental and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Market Variables, Trends, & Scope
Chapter 4. Type Business Analysis
Chapter 5. Test Business Analysis
Chapter 6. End Use Business Analysis
Chapter 7. Regional Business Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies profiled in this Lung Cancer Diagnostics market report include:- F. Hoffmann-La Roche Ltd
- Thermo Fisher Scientific
- Illumina Inc.
- Agilent Technologies
- Qiagen
- Abbott
- Bio-Rad
- Neogenomics Laboratories
- bioMérieux
- Myriad Genetics, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | August 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 12.37 Billion |
| Forecasted Market Value ( USD | $ 23.31 Billion |
| Compound Annual Growth Rate | 7.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
